Cases & Deals

  • Home
  • Practices
  • Idenix defends nucleoside analogue patent in Norway appeal against Gilead

Share

Idenix defends nucleoside analogue patent in Norway appeal against Gilead

May 2016

Client(s) Idenix Pharmaceuticals LLC

Jones Day represents Idenix Pharmaceuticals LLC (a subsidiary of Merck & Co., Inc.) in an appeal related to the validity of an Idenix patent covering nucleoside analogs and prodrugs. Subject matter is nucleoside analogs and prodrugs for treating Flaviviridae infections, including HCV. The patent covers Gilead's marketing of Sovaldi® and Harvoni® for treatment of Hepatitis C.

Idenix Pharmaceuticals LLC, et al. v. Gilead Sciences Europe Ltd., Case No. 14-117680ASD-BORG/02 (Borgarting Court of Appeal, Norway)

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.